2023
Actin Alpha 2, Smooth Muscle (ACTA2) Is Involved in the Migratory Potential of Malignant Gliomas, and Its Increased Expression at Recurrence Is a Significant Adverse Prognostic Factor
Hoshimaru T, Nonoguchi N, Kosaka T, Furuse M, Kawabata S, Yagi R, Kurisu Y, Kashiwagi H, Kameda M, Takami T, Kataoka-Sasaki Y, Sasaki M, Honmou O, Hiramatsu R, Wanibuchi M. Actin Alpha 2, Smooth Muscle (ACTA2) Is Involved in the Migratory Potential of Malignant Gliomas, and Its Increased Expression at Recurrence Is a Significant Adverse Prognostic Factor. Brain Sciences 2023, 13: 1477. PMID: 37891844, PMCID: PMC10605410, DOI: 10.3390/brainsci13101477.Peer-Reviewed Original ResearchActin alpha 2Malignant gliomasDistant recurrenceACTA2 expressionKD groupSmooth muscleSignificant adverse prognostic factorMode of recurrenceAlpha 2Progression-free survivalAdverse prognostic factorHuman malignant glioma cell linesMalignant glioma cell linesClinical glioma samplesGlioma cell linesPrognostic factorsBrain invasionTumor recurrenceInvasive tumorsNovel therapiesGlioma patientsSame patientRecurrenceControl groupPotential biomarkersPostinfantile Giant Cell Hepatitis in Native and Allograft Livers: A Multi-Institutional Clinicopathologic Study of 70 Cases
Jiao J, Chezar K, Zhang X, Wang D, Cao W, Bindu C, Chen W, Neto A, Henn P, Riahi I, Wang H, Papke D, Zhao L, Xue Y, Liao X, Zhang X. Postinfantile Giant Cell Hepatitis in Native and Allograft Livers: A Multi-Institutional Clinicopathologic Study of 70 Cases. Modern Pathology 2023, 36: 100298. PMID: 37544363, DOI: 10.1016/j.modpat.2023.100298.Peer-Reviewed Original ResearchConceptsPostinfantile giant cell hepatitisAutoimmune liver diseaseGiant cell hepatitisAlkaline phosphatase levelsClinical outcomesPhosphatase levelsLiver diseaseMulti-institutional retrospective studyAssociated with better survivalAssociated with poor survivalClinicopathological characteristics of patientsAdverse prognostic factorAssociated with autoimmune liver diseasesGiant cellsVariable clinical outcomesFollow-up resultsCharacteristics of patientsDistribution of giant cellsOlder ageLiver disease etiologyPrognostic factorsAdvanced fibrosisBetter survivalClinicopathological characteristicsLiver allografts
2022
Timing of cannabis exposure relative to prodrome and psychosis onset in a community-based first episode psychosis sample
Kline ER, Ferrara M, Li F, D'Souza DC, Keshavan M, Srihari VH. Timing of cannabis exposure relative to prodrome and psychosis onset in a community-based first episode psychosis sample. Journal Of Psychiatric Research 2022, 147: 248-253. PMID: 35066293, PMCID: PMC8882157, DOI: 10.1016/j.jpsychires.2022.01.039.Peer-Reviewed Original ResearchConceptsCannabis exposurePublic health significancePsychosis onsetPsychotic disordersHealth significanceFirst-episode psychosis samplePsychosis sampleFirst exposureFirst-episode psychosis servicesWorse premorbid functioningAdverse prognostic factorAssociation of ageImpact of cannabisPsychosis PreventionSymptom onsetPrognostic factorsOverall incidenceEarly psychosis sampleConsecutive admissionsOverall burdenPsychotic illnessPsychosis servicesPsychosis symptomsGreater severityYounger age
2021
Programmed Death Ligand-1 Expression Is Associated With Poorer Survival in Anal Squamous Cell Carcinoma.
Monsrud A, Avadhani V, Mosunjac M, Flowers L, Krishnamurti U. Programmed Death Ligand-1 Expression Is Associated With Poorer Survival in Anal Squamous Cell Carcinoma. Archives Of Pathology & Laboratory Medicine 2021, 146: 1094-1101. PMID: 34936703, DOI: 10.5858/arpa.2021-0169-oa.Peer-Reviewed Original ResearchConceptsAnal squamous cell carcinomaPD-L1 expressionHIV viral loadTumor proportion scorePD-L1Squamous cell carcinomaOverall survivalCD4 countPrognostic factorsHIV statusViral loadCell carcinomaProportion scoreInvasive anal squamous cell carcinomaMedian cancer-specific survivalIndependent adverse prognostic factorDeath ligand 1 (PD-L1) expressionCancer-specific survivalAdverse prognostic factorLigand 1 expressionSignificant prognostic factorsDeath ligand 1Kaplan-Meier curvesWorse overall survivalLog-rank test
2018
Ovarian Yolk Sac Tumors; Does Age Matter?
Conter C, Xia C, Gershenson D, Hurteau J, Covens A, Pashankar F, Krailo M, Billmire D, Patte C, Fresneau B, Shaikh F, Stoneham S, Nicholson J, Murray M, Frazier AL. Ovarian Yolk Sac Tumors; Does Age Matter? International Journal Of Gynecological Cancer 2018, 28: 77-84. PMID: 29194189, DOI: 10.1097/igc.0000000000001149.Peer-Reviewed Original ResearchConceptsOvarian yolk sac tumorEvent-free survivalYolk sac tumorOverall survivalSac tumorClinical trialsOvarian germ cell tumorsPreoperative alpha-fetoprotein levelAge cut pointStage IV diseaseAdverse prognostic factorPlatinum-based chemotherapyAlpha-fetoprotein levelsCut pointsGerm cell tumorsPediatric clinical trialsRisk of eventsOptimal cut pointJoint pediatricChemosensitive tumorsChemotherapeutic regimenPrognostic impactPrognostic factorsAdult trialsGynecologic oncologists
2017
Carbohydrate antigen 19-9 as a prognostic biomarker in pancreatic neuroendocrine tumors
Luo G, Jin K, Cheng H, Liu C, Guo M, Lu Y, Yang C, Xu J, Wang W, Gao H, Zhang S, Long J, Xu J, Ni Q, Chen J, Yu X. Carbohydrate antigen 19-9 as a prognostic biomarker in pancreatic neuroendocrine tumors. Oncology Letters 2017, 14: 6795-6800. PMID: 29163700, PMCID: PMC5688789, DOI: 10.3892/ol.2017.7071.Peer-Reviewed Original ResearchPancreatic neuroendocrine tumorsCA19-9 levelsCA19-9Carbohydrate antigen 19Overall survivalPrognostic factorsAntigen 19Neuroendocrine tumorsPrognostic biomarkerMajority of PNETsTumor node metastasis (TNM) stage IIIROC curveBaseline CA19-9 levelsSerum CA19-9 levelsMetastasis stage IIIPrimary end pointAdverse prognostic factorPatients' overall survivalExpression levelsConsecutive patientsPresent studySingle institutionAbnormal elevationStage IIINormal rangeThe prognostic value of extranodal extension in human papillomavirus‐associated oropharyngeal squamous cell carcinoma
An Y, Park HS, Kelly JR, Stahl JM, Yarbrough WG, Burtness BA, Contessa JN, Decker RH, Koshy M, Husain ZA. The prognostic value of extranodal extension in human papillomavirus‐associated oropharyngeal squamous cell carcinoma. Cancer 2017, 123: 2762-2772. PMID: 28323338, DOI: 10.1002/cncr.30598.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Squamous CellChemoradiotherapy, AdjuvantFemaleHead and Neck NeoplasmsHumansMaleMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm StagingOropharyngeal NeoplasmsOtorhinolaryngologic Surgical ProceduresPapillomaviridaePapillomavirus InfectionsPrognosisPropensity ScoreProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSquamous Cell Carcinoma of Head and NeckSurvival RateConceptsOropharyngeal squamous cell carcinomaENE-positive patientsHPV-positive oropharyngeal squamous cell carcinomaExtranodal extensionHPV-positive patientsOverall survivalPrimary surgeryPT4 tumorsAdjuvant chemoradiationConcurrent chemoradiotherapyAdjuvant treatmentPositive oropharyngeal squamous cell carcinomaPT3/pT4 tumorsMultivariable Cox regression analysisNational Cancer Data BasePredictors of OSPropensity score-matched comparisonAdjuvant concurrent chemoradiotherapyCharlson-Deyo scoreInvolved lymph nodesAdverse prognostic factorInferior overall survivalLymph node statusCox regression analysisSingle-institution study
2014
The Clinicopathologic Significance of Centromere 17 Copy Number Alterations in Invasive Breast Carcinoma
Krishnamurti U, Silverman J. The Clinicopathologic Significance of Centromere 17 Copy Number Alterations in Invasive Breast Carcinoma. Advances In Anatomic Pathology 2014, 19: 13-17. DOI: 10.1097/pcr.0000000000000016.Peer-Reviewed Original ResearchAdverse prognostic factorHER2 amplificationBreast cancerPrognostic factorsHuman epidermal growth factor receptor 2 (HER2) oncoproteinCopy number alterationsInvasive breast cancerInvasive breast carcinomaHER2/CEP17HER2 gene amplificationNumber alterationsHER2 copy numberChromosome 17 polysomyCEP17 duplicationMost patientsHER2 overexpressionBreast carcinomaClinicopathologic significanceHER2 2Chromosome 17PatientsCancerProtein overexpressionCopy numberHER2
2013
DNMT3A mutation is a poor prognosis biomarker in AML: Results of a meta-analysis of 4500 AML patients
Shivarov V, Gueorguieva R, Stoimenov A, Tiu R. DNMT3A mutation is a poor prognosis biomarker in AML: Results of a meta-analysis of 4500 AML patients. Leukemia Research 2013, 37: 1445-1450. PMID: 23962568, DOI: 10.1016/j.leukres.2013.07.032.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaAML patientsEuropean Leukemia NetDNMT3A mutationsIndependent adverse prognostic factorPoor prognosis biomarkerAdverse prognostic factorSubgroup of patientsPotential prognostic valueHigh-risk genotypesRecurrent molecular aberrationsDNMT3A mutational statusShorter OSShorter RFSYounger patientsPrognostic factorsRisk stratificationWorse prognosisPrognostic valueAML subtypesMyeloid leukemiaPrognosis biomarkerPatientsMolecular aberrationsRisk genotypes
2012
Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer
Delpech Y, Wu Y, Hess KR, Hsu L, Ayers M, Natowicz R, Coutant C, Rouzier R, Barranger E, Hortobagyi GN, Mauro D, Pusztai L. Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Research And Treatment 2012, 135: 619-627. PMID: 22890751, DOI: 10.1007/s10549-012-2194-2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Agents, HormonalBreast NeoplasmsBreast Neoplasms, MaleCarcinoma, Ductal, BreastDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateKi-67 AntigenMaleMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasms, Hormone-DependentProportional Hazards ModelsReceptors, EstrogenRetrospective StudiesTreatment OutcomeConceptsFirst-line endocrine therapyEndocrine therapyMetastatic breast cancerMetastatic diseaseKi67 expressionClinical benefitPrimary tumorBreast cancerExpression groupEstrogen receptor-positive metastatic breast cancerIndependent adverse prognostic factorKaplan-Meier survival curvesClinical benefit rateKi67 expression levelsAdverse prognostic factorMedian survival timeLow Ki67 expressionBreast cancer correlatesHigh Ki67 expressionHigh clinical benefitPrognostic factorsMedian timeMetastatic recurrencePrimary cancerImmunohistochemical variables
2010
Worsening Renal Function Defined as an Absolute Increase in Serum Creatinine Is a Biased Metric for the Study of Cardio-Renal Interactions
Testani JM, McCauley BD, Chen J, Shumski M, Shannon RP. Worsening Renal Function Defined as an Absolute Increase in Serum Creatinine Is a Biased Metric for the Study of Cardio-Renal Interactions. Cardiology 2010, 116: 206-212. PMID: 20689277, PMCID: PMC2992648, DOI: 10.1159/000316038.Peer-Reviewed Original ResearchConceptsBaseline renal functionCardio-renal interactionsRenal functionSerum creatinineHeart failureStrong adverse prognostic factorAbsolute increaseBaseline renal insufficiencyDecompensated heart failureAdverse prognostic factorPrediction of mortalityRenal insufficiencyPrognostic factorsDischarge diagnosisConsecutive admissionsUnadjusted associationsCreatinineAbsolute changeAdmissionDlFuture studiesGFRFailureInsufficiencyMortality
2009
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
Heng D, Xie W, Regan M, Warren M, Golshayan A, Sahi C, Eigl B, Ruether J, Cheng T, North S, Venner P, Knox J, N. K, Kollmannsberger C, McDermott D, Oh W, Atkins M, Bukowski R, Rini B, Choueiri T. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study. Journal Of Clinical Oncology 2009, 27: 5794-5799. PMID: 19826129, DOI: 10.1200/jco.2008.21.4809.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBenzenesulfonatesBevacizumabCarcinoma, Renal CellFemaleHumansIndolesKidney NeoplasmsMaleMiddle AgedNiacinamidePhenylurea CompoundsPrognosisPyridinesPyrrolesSorafenibSunitinibSurvival RateVascular Endothelial Growth Factor AConceptsMetastatic renal cell carcinomaMemorial Sloan-Kettering Cancer CenterRenal cell carcinomaMedian OSAdverse prognostic factorOverall survivalPrognostic factorsVascular endothelial growth factorCell carcinomaMemorial Sloan-Kettering Cancer Center modelVascular endothelial growth factor-targeted agentGrowth factor-targeted agentsIndependent adverse prognostic factorTreated with vascular endothelial growth factorCancer CenterPredictor of shorter survivalFavorable-risk groupVEGF-targeted agentsPoor-risk groupTreated with sunitinibIntermediate-risk groupMedian Follow-UpCox proportional hazards regressionKarnofsky performance statusCanadian cancer centersPoor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma
Krishnamurti U, Hammers J, Atem F, Storto P, Silverman J. Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Modern Pathology 2009, 22: 1044-1048. PMID: 19396150, DOI: 10.1038/modpathol.2009.61.Peer-Reviewed Original ResearchConceptsInvasive breast carcinomaChromosome 17 polysomyBreast carcinomaHER2 gene amplificationBreast cancerChromosome 17 aneusomyHuman epidermal growth factor receptor 2 (HER2) oncoproteinAdverse prognostic factorAdverse prognostic indicatorEstrogen receptor negativityTreatment of patientsHigh nuclear gradePoor prognostic significanceGene amplificationPaucity of literatureReceptor negativityMost patientsPathologic factorsPrognostic factorsPredictive factorsPrognostic significanceHistologic gradePrognostic indicatorTumor stageHER2 overexpression
2008
Impact of Nutrition and Exercise on Cancer Survival
Irwin ML, Mayne ST. Impact of Nutrition and Exercise on Cancer Survival. The Cancer Journal 2008, 14: 435-441. PMID: 19060611, DOI: 10.1097/ppo.0b013e31818daeee.Peer-Reviewed Original ResearchConceptsCancer survivorsSupplement useCancer survivalAdverse prognostic factorPhysical activity recommendationsNutrient supplement useAmerican Cancer SocietyLifestyle-based approachLong-term survivalImpact of nutritionLifestyle interventionPrognostic factorsRandomized trialsCancer outcomesPhysical inactivityActivity recommendationsCurrent guidelinesNumber of menCancer SocietyPhysical activityWeight gainAvailable evidenceSurvivorsSurvivalObesityInfluence of Activation State of ErbB-2 (HER-2) on Response to Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil for Stage II, Node-Positive Breast Cancer: Study 8541 From the Cancer and Leukemia Group B
DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, Liu ET, Muss HB, Berry DA, Hayes DF, Thor AD. Influence of Activation State of ErbB-2 (HER-2) on Response to Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil for Stage II, Node-Positive Breast Cancer: Study 8541 From the Cancer and Leukemia Group B. Journal Of Clinical Oncology 2008, 26: 2364-2372. PMID: 18390970, PMCID: PMC6589994, DOI: 10.1200/jco.2007.13.6580.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantCyclophosphamideDisease-Free SurvivalDose-Response Relationship, DrugDoxorubicinEnzyme ActivationFemaleFluorouracilGene DosageHumansImmunohistochemistryIn Situ Hybridization, FluorescenceLymphatic MetastasisNeoplasm StagingPhosphorylationReceptor, ErbB-2ConceptsLeukemia Group BAdjuvant cyclophosphamideErbB-2Breast cancerGroup BAnthracycline-based adjuvant chemotherapyNode-positive breast cancerAdverse prognostic factorSpecific chemotherapeutic agentsErbB-2 overexpressionActivation stateTumor tissue sectionsAdjuvant chemotherapyCAF doseCALGB 8541Fluorouracil chemotherapyPrognostic factorsAssessable casesFavorable outcomePatientsChemotherapeutic agentsStage IICancerDoseTissue sections
2007
High Resolution Array-CGH in Splenic Marginal Zone B-Cell Lymphoma: Correlation of Copy Number Imbalances with HCV Status and Prognostic Categories.
Novara F, Arcaini L, Merli M, Passamonti F, Zibellini S, Montanari F, Rizzi S, Rumi E, Pascutto C, Paulli M, Zuffardi O, Lazzarino M. High Resolution Array-CGH in Splenic Marginal Zone B-Cell Lymphoma: Correlation of Copy Number Imbalances with HCV Status and Prognostic Categories. Blood 2007, 110: 2620. DOI: 10.1182/blood.v110.11.2620.2620.Peer-Reviewed Original ResearchSplenic marginal zone B-cell lymphomaMarginal zone B-cell lymphomaPrognostic categoriesNumber of CNAsB-cell lymphomaCopy number alterationsHCV casesVillous lymphocytesGenetic alterationsAdverse prognostic factorRecent multicentre studyPeripheral blood lymphocytesDifferent prognostic categoriesFrequent copy number alterationsGroups of ptsImmunoglobulin variable heavy chain genesSpecific genetic abnormalitiesSpecific genetic alterationsVariable heavy chain genesAutoimmune backgroundHCV infectionHCV statusPrognostic factorsClinical featuresMulticentre studyEvaluation of the prognostic significance of human kallikrein 8 protein expression levels in advanced ovarian cancer by using automated quantitative protein analysis
Kountourakis P, Psyrri A, Scorilas A, Markakis S, Kowalski D, Camp R, Diamandis E, Dimopoulos M. Evaluation of the prognostic significance of human kallikrein 8 protein expression levels in advanced ovarian cancer by using automated quantitative protein analysis. Journal Of Clinical Oncology 2007, 25: 5581-5581. DOI: 10.1200/jco.2007.25.18_suppl.5581.Peer-Reviewed Original ResearchOvarian cancerProtein expression levelsPrognostic significanceSurvival analysisPlatinum-paclitaxel combination chemotherapyYear progression-free survivalAdvanced stage ovarian cancerExpression levelsProgression-free survivalAdvanced ovarian cancerAdverse prognostic factorDisease-free survivalStage ovarian cancerUnivariate survival analysisMultivariate survival analysisKallikrein-8Important prognostic biomarkerSerine protease enzyme familyFree survivalSurgical debulkingCombination chemotherapyPrognostic factorsPrognostic valueResidual diseaseClinicopathological variables
1999
Downregulation of p27KIP1 and Ki67/Mib1 Labeling Index Support the Classification of Thyroid Carcinoma Into Prognostically Relevant Categories
Tallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S, Carcangiu M. Downregulation of p27KIP1 and Ki67/Mib1 Labeling Index Support the Classification of Thyroid Carcinoma Into Prognostically Relevant Categories. The American Journal Of Surgical Pathology 1999, 23: 678-685. PMID: 10366150, DOI: 10.1097/00000478-199906000-00007.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, FollicularAdultAgedCarcinoma, PapillaryCell Cycle ProteinsCyclin-Dependent Kinase Inhibitor p27Cyclin-Dependent KinasesDisease-Free SurvivalDown-RegulationFemaleHumansImmunoenzyme TechniquesKi-67 AntigenMaleMicrotubule-Associated ProteinsMiddle AgedPrognosisThyroid NeoplasmsTumor Suppressor ProteinsConceptsKi67/MIB1 labeling indexLow p27Kip1 expressionMIB1 labeling indexThyroid carcinomaFollicular carcinomaP27Kip1 expressionPathologic featuresPrognostic groupsTumor differentiationLabeling indexFavorable pathologic featuresKi67/MIB1Unfavorable pathologic featuresAdverse prognostic factorLarger tumor sizeFollicular cell originDownregulation of p27Kip1Valuable prognostic indicatorCellular proliferationCellular proliferation patternsCyclin-dependent kinase inhibitor p27Kip1High proliferative rateLow p27Kip1Prognostic factorsTumor size
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply